Friedhelm Blobel, Ph.D.
Friedhelm Blobel, Ph.D., has served as our President, Chief Executive Officer and a Director since June 2006. From July 2000 to 2006, Dr. Blobel was President, Chief Executive Officer and a Director of Gryphon Therapeutics, Inc., a South San Francisco-based biopharmaceutical company. Prior to joining Gryphon Therapeutics in July 2000, Dr. Blobel spent more than two decades as an executive with the Hoechst Group and the Boehringer Mannheim Group, including responsibilities in the areas of diabetes and in vitro diagnostics. His roles at these companies included Group President of several product divisions, Chief Technology Officer and General Manager in Tokyo, Japan of a marketing and sales joint venture between Boehringer and Yamanouchi Pharmaceuticals (now Astellas Pharma, Inc.), Senior Vice President of Research and Development Diabetes and Patient Care in Mannheim, Germany as well as in Indianapolis, Indiana. Dr. Blobel earned his doctorate degree (“Dr.rer.nat.”; a Ph.D. equivalent) with a dissertation in Biochemistry and Microbiology from the University of Hohenheim, Germany and holds an advanced degree in Chemistry from the University of Stuttgart, Germany.
Hong Zhao
Hong Zhao joined SciClone as Chief Executive Officer, China Operations, in March 2013. Mr. Zhao joins SciClone from Simcere Pharmaceutical Group, where he served as Executive Vice President, responsible for all business operations, including leading a sizeable sales team and managing multiple business units, and had direct reporting responsibility for medical affairs, market access, marketing and sales operations, training and personnel development. Prior to Simcere, he held positions of increasing seniority at Novartis China, from Regional Sales Manager, National Sales Director, Vice President, Senior Vice President of Novartis Greater China and General Manager of Novartis Shanghai. Mr. Zhao also served with Xi’an Janssen Pharmaceutical, where he rose quickly from Medical Representative to District Sales Manager. Earlier in his career he served as a lecturer and tutor at Nanjing Medical College. Mr. Zhao earned a Bachelor of Medicine degree from Nanjing Medical College and an Executive Masters of Business Administration degree from China European International Business School (CEIBS) in Shanghai.
Min Yin
Min Yin has served as our Vice President of Compliance and Internal Audit since October 2011. Prior to joining SciClone, she served as Finance Director at Leica Microsystems China. From 2009 to 2010 Ms. Yin was with Beijing Novartis Pharma LTD and served as Senior Director, Finance & Commercial, Oncology. Ms. Yin also held Finance Director positions with Boston Scientific International Medical Trading Corporation from 2004 to 2009 and Valmont Industries, a manufacturer of steel structured poles for lighting, from 1996 to 2004. Ms. Yin holds a Bachelors of Business Administration from the University of Nebraska at Omaha, and a Masters of Business Administration from the University of New Jersey and is a Certified Public Accountant.
Stephanie Wong
Stephanie Wong joined SciClone in 2009 and currently serves as Vice President, Finance and Controller. Prior to joining SciClone, she served as Senior Director, Finance at AcelRx Pharmaceuticals. From 2001 to 2008 Ms. Wong held various positions at Kosan Biosciences, a publicly traded biotechnology company until its acquisition by Bristol-Myers Squibb, most recently as Senior Director and Controller. Prior to that, Ms. Wong worked as an audit manager at PricewaterhouseCoopers. Ms. Wong holds a Bachelor of Science degree in Business Administration from the University of California, Berkeley and is a Certified Public Accountant.
Lan Xie
Lan Xie joined SciClone as Vice President, Finance and Chief Financial Officer, China Operations in 2012. Ms. Xie has more than 18 years of experience in financial management and operations in the US and China. Her professional experience includes: Shangpharma Corp. where she was VP Finance and IR, and successfully listed the company in the US; PriceWaterhouseCoopers in Shanghai, where she was senior manager, transaction services; Deloitte & Touche in NY, where she was manager, mergers and acquisitions; Reuters Incorporated, where she was finance manager, special projects; and PriceWaterhouseCoopers in Boston where she was a senior associate. She is a US CPA and received her MBA from INSEAD, Singapore/France.
Robert King, Ph.D.
Robert King joined SciClone as Vice President, Product Development and Manufacturing in 2011. At SciClone, Dr. King oversees the manufacturing of active pharmaceutical ingredients (API), drug products, quality control and directs activities related to chemistry, manufacturing and controls (CMC). Robert has over 20 years of experience in the pharmaceutical industry, most recently as Vice President, Product Development and Manufacturing at Bayhill Therapeutics. Prior to Bayhill, Dr. King was VP, Product Development and Manufacturing at Rinat Neuroscience Corporation (a division of Pfizer Global R & D). Dr. King has also worked at a number of biotechnology companies, including Millennium Pharmaceuticals, COR Therapeutics, Inc., Scios and Molecular Devices Corporation. Dr. King has a PhD in Chemical Engineering from UC Berkeley and a BS in Chemical Engineering from the University of Washington.
Cynthia W. Tuthill, Ph.D.
Cynthia W. Tuthill, Ph.D ., Senior Vice President, Scientific Affairs, and Chief Scientific Officer, has over 20 years of experience in the biotechnology and pharmaceutical industries. Dr. Tuthill has been with SciClone since 1991, where she is responsible for design and oversight of all nonclinical studies, leads several clinical development projects, and oversees both project management and manufacturing. Prior to joining SciClone, Dr. Tuthill was a senior product development scientist at Becton Dickinson Immunocytometry Systems, responsible for development of manufacturing methods, according to Good Manufacturing Processes, for new reagents for the assessment of viral diseases. From 1984 to 1990, she was a senior scientist at California Biotechnology, Inc. (now Scios, Inc.). At California Biotechnology she was project manager for several large heart disease therapeutic projects, as well as being responsible for analysis and purification of recombinant human proteins. Dr. Tuthill earned her undergraduate degree, summa cum laude, from the University of California , Berkeley , and her Ph.D. in protein biochemistry with highest honors from Harvard University.